Ruxolitinib as Salvage Therapy in Steroid Refractory Acute Graft Versus Host Disease in Pediatric Hematopoietic Stem Cell Transplant Patients
Highlights • Ruxolitinib has a 45% overall response rate as salvage therapy in children with steroid- refractory acute graft versus host disease • Ruxolitinib is associated with significant but reversible adverse effects such as cytopenias and transaminitis
Saved in:
Published in | Biology of blood and marrow transplantation Vol. 23; no. 7; pp. 1122 - 1127 |
---|---|
Main Authors | , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
United States
Elsevier Inc
01.07.2017
|
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Highlights • Ruxolitinib has a 45% overall response rate as salvage therapy in children with steroid- refractory acute graft versus host disease • Ruxolitinib is associated with significant but reversible adverse effects such as cytopenias and transaminitis |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 |
ISSN: | 1083-8791 1523-6536 |
DOI: | 10.1016/j.bbmt.2017.03.029 |